All terms
Clinical & TrialsClinical Evidence
Surrogate Endpoint
Biomarker or intermediate outcome used as a substitute for a clinical endpoint in regulatory decisions.
Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026
Definition
Surrogate endpoints (e.g., HbA1c for glycemic control, blood pressure for cardiovascular risk) shorten trial duration but require evidence that change in the surrogate predicts clinically meaningful benefit. What the regulation says
The FDA recognizes surrogate endpoints as measures that can be used in clinical trials to predict a clinical benefit, as outlined in guidance documents such as the “Guidance for Industry, FDA Staff, and Other Stakeholders: Expedited Programs for Serious Conditions-Drugs and Biologics.” The EU Medical Device Regulation (EU MDR) does not explicitly detail surrogate endpoints; however, the principles of clinical evidence and demonstration of safety and performance (Annex I, Chapter I, Section 1 and 3) necessitate that endpoints, including surrogates, reliably demonstrate clinical benefit. Regulators emphasize that a surrogate endpoint must be validated to show it is a reasonable predictor of a clinically meaningful outcome.What this means in practice
Increasingly important for IVD and digital biomarker submissions; FDA maintains a Surrogate Endpoint Table for drug approvals that informs device thinking.Examples
- A trial for a new diabetes management app uses a reduction in HbA1c levels as a surrogate endpoint to demonstrate improved glycemic control over a shorter trial period, rather than waiting for long-term cardiovascular events.
- A diagnostic test for early cancer detection utilizes a specific biomarker level as a surrogate endpoint, which has been shown to correlate with definitive pathological diagnosis.
- A medical device designed to treat hypertension employs sustained reductions in blood pressure readings as a surrogate endpoint, with extensive prior evidence linking this to reduced risk of stroke and heart attack.
Common pitfalls
- •Over-reliance on a surrogate endpoint without sufficient clinical validation can lead to regulatory rejection.
- •Selecting a surrogate endpoint that does not accurately reflect the patient population or disease progression is a common mistake.
- •Failing to establish a clear and evidence-backed correlation between the surrogate endpoint and the true clinical outcome is a critical pitfall.
- •Underestimating the data requirements for validating a surrogate endpoint can delay trial progress.
Frequently asked questions
Surrogate endpoints are used to shorten the duration and reduce the cost of clinical trials by providing an earlier indication of a treatment's effect, particularly for diseases with long-term primary outcomes.
Related terms
Shared paths + categoryClinical & Trials
Composite Endpoint
Single endpoint combining multiple component outcomes (e.g., MACE = death + MI + stroke).
Same category
Clinical & Trials
Minimal Clinically Important Difference(MCID)
Smallest change in a measurement that patients perceive as clinically meaningful.
Same category
Clinical & Trials
Adverse Event(AE)
Any untoward medical occurrence in a subject, whether or not related to the device.
Clinical Trials & Evidence · adjacent
Clinical & Trials
Primary and Secondary Endpoints
The pre-specified outcomes that determine trial success (primary), provide supporting evidence (secondary), or generate hypotheses (exploratory).
Clinical Trials & Evidence · adjacent
Clinical & Trials
Adaptive Trial Design
Trial design that pre-specifies opportunities to modify aspects (sample size, arms, endpoints) based on interim data.
Clinical Trials & Evidence
Clinical & Trials
Clinical Evaluation Report(CER)
Documented assessment of clinical data demonstrating EU MDR conformity for a device.
Clinical Trials & Evidence
Latest in MedTech
Primary references
3 sourcesLink health: 3 verified· last checked 2026-06-20
FDA·2ISO·1
- 1FDA Surrogate EndpointsVerifiedFDAfda.gov
- 2ISO 14155 Standard PageVerifiedISOiso.org
- 3FDA - Clinical Trials and Human Subject ProtectionVerifiedFDAfda.gov
Inline markers like [1] jump to the matching reference above.